Bush Administration Nominates von Eschenbach to Head FDA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bush Administration Nominates von Eschenbach to Head FDA


ePT--the Electronic Newsletter of Pharmaceutical Technology

Bush Administration Nominates von Eschenbach to head FDA

The Ides of March brought good news to US Food and Drug Administration (Rockville, MD, www.fda.gov) Acting Commissioner Andrew von Eschenbach. The White House announced his nomination to the job on a permanent basis. Von Eschenbach has been the acting head of FDA since former commissioner Lester Crawford resigned in September 2005. As acting head, von Eschenbach’s decision to keep his job as chief of the National Cancer Institute has raised criticism and conflict-of-interest concerns; if confirmed he will have to drop his other hat.

Although he has strong support from pharma and other industries regulated by FDA, von Eschenbach will face a tough confirmation process in the Senate. FDA’s delayed action on approving an OTC version of the morning-after pill Plan B once again is likely to dominate the discussion, along with safety concerns about drugs and medical devices.
White House staffers evidently interviewed a number of outside candidates, but had difficulty finding someone with equally strong medical and research credentials who is familiar with FDA regulatory issues and meets administration political criteria. Everyone agrees that FDA needs a permanent leader, but getting there will not be that easy. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here